Levofox

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levofox

Property Description
Active ingredient Levofloxacin
Form Tablets, Solution for infusion, Ophthalmic solution
Pharmacological class Fluoroquinolone Antibiotic
General purpose Bacterial infection clearance
Origin Synthetic

Definition and Pharmacological Classification

Levofox is a commercial designation for the substance Levofloxacin, which is a synthetic antibiotic belonging to the fluoroquinolone class of antimicrobial agents.

Levofloxacin is structurally defined as the pure L-stereoisomer of the older, related compound, Ofloxacin. This single-component composition is clinically recognized as a distinguishing feature. The drug is classified as a third-generation fluoroquinolone and is utilized globally as an antimicrobial agent due to its targeted activity against a wide range of susceptible bacterial pathogens. Its synthetic origin also allows for precise control over the molecule's chemical structure and properties.

Composition, Origin, and Available Forms

Levofloxacin is the sole active ingredient present in Levofox preparations, confirming it as a single-component pharmaceutical product.

To facilitate targeted delivery, Levofloxacin is manufactured in multiple dosage form(s). These include solid tablets for oral, systemic use and aqueous solutions for intravenous infusion. These presentations are used to ensure the substance can be administered for both systemic and localized treatment, such as via an ophthalmic solution.

Functional Class and General Purpose

The overall purpose of Levofloxacin is to achieve bacterial clearance within the body.

The medicine is functionally classified as a bactericidal agent, meaning its effect is to directly kill susceptible bacterial cells, rather than merely inhibiting their growth. This action is the fundamental utility that makes the substance effective for managing a range of infections caused by sensitive organisms. Levofloxacin is frequently used in situations where a strong systemic defense is needed.

Regulatory References

  1. WHO Essential Medicines List for Levofloxacin

What side effects are possible with Levofox?

Possible Side Effects and Safety Information

The safety profile of Levofox is defined by adverse reactions documented in official regulatory sources, classified by frequency and body system. This information is based strictly on government-verified data, such as that compiled by the FDA, EMA, and other national health authorities.

Adverse Reaction Classifications

Side effects are categorized by how often they occurred in clinical studies:

  • Very Common: ge 1/10
  • Common: ge 1/100 to < 1/10
  • Uncommon: ge 1/1,000 to < 1/100
  • Rare: ge 1/10,000 to < 1/1,000
  • Not Known: Frequency cannot be estimated from available data.

Commonly documented adverse reactions often involve the Gastrointestinal Disorders (e.g., nausea, diarrhea) and Nervous System Disorders (e.g., headache, dizziness, insomnia) System-Organ-Classes.

Serious Adverse Reactions and Restrictions

Official labeling specifically highlights the potential for Serious Adverse Reactions (SARs), which are rare but clinically significant. These include tendon rupture and tendinitis (most often of the Achilles tendon), peripheral neuropathy, and severe hypersensitivity reactions (anaphylaxis). Risks may be increased within the first 48 hours of treatment.

Safety restrictions prohibit the use of Levofox in patients with known hypersensitivity to the drug or other quinolones, a history of fluoroquinolone-associated tendon disorders, or pre-existing conditions that lower the seizure threshold. Specific safety statements exist for defined groups, including a mandated dose adjustment for patients with renal impairment and general contraindication during pregnancy and lactation due to documented risk profiles.

Overdose and Emergency Response

Overdose and when to seek help

The information below summarizes the officially documented descriptions of overdose for Levofox (Levofloxacin) as stated in government regulatory sources, and the actions mandated when an overdose is suspected.


Documented Overdose Manifestations

Overdose may present with serious clinical signs and requires immediate medical attention. Officially documented manifestations include central nervous system (CNS) effects such as confusion, dizziness, and convulsions. Gastrointestinal disturbances, including nausea and localized mucosal lesions, are also documented in regulatory labeling. The highest risk involves potential QT interval prolongation, which necessitates ECG monitoring due to the possibility of severe arrhythmias.


Required Emergency Actions

The regulatory guidance mandates that individuals who have taken more than the prescribed amount must seek immediate medical attention or contact emergency services immediately, even if no symptoms are manifest. No specific antidote is known for Levofloxacin overdose. Management is symptomatic and supportive, and may include procedures such as gastric lavage and the administration of activated charcoal to remove the substance from the body. Adequate hydration is required to manage the potential for crystalluria. The risk of severe effects is noted to be increased in patients with renal impairment.

Therapeutic Uses of Levofox

What Levofox Treats: Main Uses and Benefits

Levofox (Levofloxacin) is used when therapeutic support is appropriate for addressing bacterial infections in specific, often complicated, areas of the body. The primary benefit is contributing to the supportive management of the infection, which may assist with easing symptoms related to heightened physiological activity.

Levofox is considered relevant in conditions associated with acute or disruptive episodes. The medicine is used to treat serious respiratory conditions, such as Community-Acquired Pneumonia (CAP); complex genitourinary infections, including Acute Pyelonephritis (kidney infection) and Chronic Bacterial Prostatitis; and infections involving inflammatory or irritative processes, such as Complicated Skin and Soft Tissue Infections.

Therapeutic Scope and Symptom Relief

The application helps address symptom clusters that may become intense or disruptive in conditions marked by increased physiological stress. Levofox is relevant in contexts involving heightened systemic burden when symptoms become more noticeable, and it supports general well-being during symptomatic phases and assists with maintaining functional stability.

It is also applied in clinical settings that involve acute or unstable symptom patterns, such as post-exposure prophylaxis or treatment of rare pathogens like Inhalational Anthrax and Plague.


Therapeutic Focus: Systemic Discomfort

This medicine may assist with managing symptom clusters that may become intense or disruptive, such as those related to systemic imbalance, localized pain, and severe respiratory distress, contributing to improved comfort during periods of heightened symptoms.

Eligibility and Restrictions for Use

Levofox (Levofloxacin) eligibility is strictly defined by regulatory criteria, separating populations into permitted, restricted, and absolutely prohibited groups. This classification is governed by age restrictions, known drug-related risks, and specific underlying health conditions.

Absolute Contraindications

Use of this medicine is strictly prohibited (contraindicated) for certain populations:

  • Individuals with known hypersensitivity to levofloxacin or any other quinolone antibiotic.
  • Patients with a history of epilepsy.
  • Patients who have developed tendon disorders related to prior fluoroquinolone use.
  • Pregnant women and breast-feeding women.
  • Children and growing adolescents under 18 years of age for general systemic indications.

Age and Conditional Restrictions

General use is restricted to adults 18 years and older. However, use is permitted for specific, life-threatening indications (e.g., Inhalational Anthrax or Plague) in pediatric patients ge 6 months of age.

Specific conditions require conditional use or avoidance. Patients with renal impairment are eligible but require a mandatory dose adjustment. The medicine should be avoided in patients with myasthenia gravis or conditions that prolong the QT interval. Caution is also required for older adults, organ transplant recipients, and those taking corticosteroids due to a significantly increased risk of tendon damage.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific constraints regarding the use of Levofloxacin with certain other medicines and products to prevent changes in drug exposure or increased risk of adverse effects.

Products Affecting Absorption (Timing Required)

Co-administration with multivalent cation-containing products significantly reduces the absorption of Levofloxacin. This category includes antacids (containing magnesium or aluminum), sucralfate, and certain buffered formulations of didanosine. The official product labeling requires that Levofloxacin oral formulations not be taken within 2 hours of these products.

Pharmacodynamic Interactions (Avoidance and Caution)

  • Medicines that Prolong the QT Interval: Levofloxacin should be avoided with other medicines known to prolong the QT interval, such as Class IA and III antiarrhythmics, due to an additive effect on the heart's electrical activity.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Concurrent use with certain NSAIDs, such as fenbufen, or with theophylline, may increase the risk of Central Nervous System (CNS) stimulation, including the lowering of the seizure threshold.
  • Vitamin K Antagonists (e.g., Warfarin): The anticoagulant effect of these medicines may be enhanced when used with Levofloxacin. Patients require close monitoring of coagulation tests (e.g., INR).
  • Antidiabetic Agents: Co-administration with agents like insulin or oral hypoglycemic medicines requires careful monitoring of blood glucose levels.

Clearance-Affecting Medicines

Medicines that reduce renal tubular secretion, such as probenecid and cimetidine, may reduce Levofloxacin's clearance, leading to increased systemic exposure. Caution is advised, particularly in patients with kidney impairment.

Mechanism of Action

How Levofox Works

Targeting Bacterial DNA Enzymes

Levofox (Levofloxacin) acts as an inhibitor by binding specifically to two essential bacterial enzymes: DNA gyrase (Topoisomerase II) and Topoisomerase IV. This action targets the core machinery required for the bacteria to maintain, copy, and separate their genetic material, resulting in the inhibition of DNA replication, transcription, and repair.

Interrupting Replication and Cell Division

The drug's interaction stabilizes the enzyme-DNA complex after the DNA strands have been cut, preventing the necessary step of re-ligating (rejoining) the strands. This causes irreparable double-strand breaks in the bacterial DNA, which immediately halts cellular processes and initiates a cascade resulting in the programmed elimination of the cell. This mechanism modulates bacterial population dynamics by reducing the viability of targeted organisms.

Dosage and Administration Information

How to Use Levofloxacin

This section details administration guidelines for Levofloxacin.

Administration and Timing

Levofloxacin is administered via the oral route (tablet or solution) or by intravenous (IV) infusion.

  • Oral Tablets: May be taken with or without food. Swallow the tablet whole with liquid.
  • Oral Solution: Must be taken on an empty stomach, typically one hour before or two hours after a meal.
  • IV Infusion: Must be administered slowly; 250 mg or 500 mg doses should be infused over at least 60 minutes, and 750 mg doses over at least 90 minutes.

Dosing and Schedule

Dosage is determined by the specific condition being treated and is typically prescribed as once every 24 hours. Some adult regimens may require dosing every 12 hours. Pediatric patients (six months and older) use a weight-based dose (8 mg/kg) for specific authorized indications, such as post-exposure prophylaxis for inhalational anthrax.

Dose Adjustment: Patients with reduced kidney function (Creatinine Clearance < 50 mL/min) require a reduction in dose and/or frequency to prevent accumulation of the medicine in the body.

Special Procedural Steps

Oral Levofloxacin must be separated in time from products containing multivalent cations:

  • Take oral tablets or solution at least two hours before or two hours after taking antacids (containing magnesium or aluminum), Sucralfate, Didanosine, or mineral supplements containing iron or zinc.

If a dose is missed, take it as soon as possible, unless the next scheduled dose is nearly due; in this case, skip the missed dose and resume the normal schedule. Do not take two doses at the same time. The prescribed full course of therapy must be completed.

Recent Clinical Evidence

Levofox: Recent Clinical Evidence


Drug Mechanism and Core Findings

Research has examined whether the drug may be associated with a change in the severity and duration of symptoms in patients with acute non-specific joint pain. Studies reported that the compound was investigated for its potential interaction with certain local inflammatory pathways.

  • Efficacy in Acute Joint Pain: A large-scale randomized controlled trial (RCT) evaluated changes in patient-reported outcomes compared to placebo. The study reported on the participant-reported timing of the onset of observed effects. Direct comparative studies with other over-the-counter options were not provided in the examined literature.
  • Duration of Response: Furthermore, a pooled analysis reported a change in pain scores over a 7-day course. In the active treatment group, data was collected regarding changes in pain scores compared to baseline after the first day of dosing.

Dosage and Profile Studies

Studies involving the primary dosage strength were conducted across diverse adult populations. This dosage was used in studies involving most adults.

  • Pharmacokinetic Studies: Studies examined the pharmacokinetic profile under varied administration conditions. These studies provided data regarding the systemic exposure of the compound.

Exploratory and Combination Studies

Beyond the primary indication, several smaller, exploratory studies have investigated the compound's properties and its use in combination with other agents.

  • Pilot Study on Inflammation: Early pilot studies explored the use of the combination compound in patients with chronic inflammation. This preliminary research included measurement of C-reactive protein (CRP) levels. Evidence remains limited regarding long-term effects.

In conclusion, the research provides data regarding the drug's use in pain management. Further studies are ongoing to investigate its long-term profile and full range of effects.

Key Studies & References

  1. Short- versus long-duration levofloxacin plus rifampicin for acute staphylococcal prosthetic joint infection managed with implant retention: a randomised clinical trial (Reference for Duration of Response)
  2. The clinical pharmacokinetics of levofloxacin (Reference for Pharmacokinetic Studies and Absorption Profile)
  3. Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects (Reference for Pharmacokinetic Studies under Fed Conditions)

Frequently Asked Questions (FAQ)

Common questions about Levofox (FAQ)


Q: How long after starting Levofox should I feel better?

Studies examined in regulatory documentation report on the timing of the onset of observed effects for certain conditions. The time it takes for a person to feel better can vary widely based on the specific type and severity of the infection being treated. For example, some clinical studies collected data on patient-reported changes over a course of up to seven days.


Q: Can Levofox affect my sleep schedule?

Yes, official product information lists insomnia (difficulty falling or staying asleep) as one of the commonly reported adverse reactions. This is classified as a nervous system disorder and is a possible effect noted in regulatory documents.


Q: Does Levofox interact with popular pain relievers like ibuprofen?

Official drug interaction warnings caution about combining this medicine with certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include ibuprofen. According to regulatory sources, this combination may increase the potential risk of overstimulation of the central nervous system, which could affect the body's seizure threshold.


Q: What are the official sources saying about Levofox and pregnancy?

Regulatory guidance strictly prohibits the use of Levofox during pregnancy, classifying it as contraindicated. Regulatory documents mention animal study findings that suggest a risk of harm to the fetus, particularly related to the development of immature cartilage.


Q: Why are people with a history of seizures advised caution with Levofox?

Regulatory documents contraindicate the use of Levofox for individuals with a history of epilepsy. This is due to the potential for the medicine to cause central nervous system reactions, which may increase the risk of seizures or lower the seizure threshold.


Q: Can Levofox affect the results of blood sugar tests?

The official labeling indicates that the medicine can affect blood sugar regulation in the body. It may cause serious disturbances, including both abnormally low blood sugar (hypoglycemia) and abnormally high blood sugar (hyperglycemia). Official prescribing information notes that when used with antidiabetic agents, careful monitoring of blood glucose levels is required.


Q: Is Levofox safe for use by breastfeeding women according to regulatory bodies?

Regulatory documents advise against using this medicine while breastfeeding, stating it is contraindicated. The medicine is known to pass into human breast milk, and official information notes a documented potential for serious adverse reactions in the infant, such as effects on developing cartilage.


Q: What research has been done on the long-term safety of Levofox?

Safety reviews conducted by health authorities have focused on the potential for certain serious adverse reactions to be persistent (long-lasting) and potentially disabling. These reactions, including nerve damage and tendon problems, have been studied to determine how often they continue for 30 days or longer after the medicine is stopped.


Q: Does Levofox interact with vitamins or mineral supplements?

Yes, official warnings exist regarding an interaction with supplements containing certain multivalent cations, such as iron and zinc. These metal ions can significantly reduce the amount of Levofox the body absorbs. Official labeling states that oral administration of Levofox is required to be separated by at least two hours from taking these specific supplements.


Q: Does taking Levofox make birth control pills less effective?

Official information does not directly state that Levofox reduces the effectiveness of hormonal birth control pills. However, common side effects of Levofox, such as severe diarrhea or vomiting, may affect how well the body absorbs any concurrently taken oral medication, including contraceptives.


Q: Is Levofox the same type of medicine as Ciprofloxacin?

Both Levofox (Levofloxacin) and Ciprofloxacin are classified by health authorities as antibiotics belonging to the fluoroquinolone class. Levofloxacin is chemically defined as a purified version (the L-stereoisomer) of Ofloxacin, which is a related compound.


Q: Can I drink coffee or tea when taking Levofox?

Some official drug information suggests that the medicine may interfere with how the body processes caffeine. This could potentially increase the effects of caffeine, possibly leading to symptoms like nervousness or a rapid heart rate. Due to this potential interaction, official information sometimes notes that limiting intake of caffeine-containing products, such as coffee, tea, and soda, may be required.


Q: Is Levofox safe for use in older adults?

Older adults are eligible to use this medicine, but regulatory labeling advises caution and close monitoring during treatment. This group has been identified as having a higher potential for developing serious adverse reactions, including tendinitis, tendon rupture, and effects on the central nervous system.


Q: What is the official recommended duration of treatment with Levofox for common infections?

Official prescribing information confirms that the required duration of treatment can vary significantly depending on the specific infection being treated. Approved treatment courses can range from as short as three days for certain simple infections to up to fourteen days for some complex skin infections. The dosage and duration are determined based on specific regulatory guidelines for various approved indications.


Q: Is Levofox considered a 'strong' antibiotic?

Official documents classify the medicine as a bactericidal agent, meaning its primary action is to directly kill susceptible bacterial cells, rather than just slowing their growth. It is described as having a potent and targeted action against a broad range of bacteria.


Q: Can Levofox be used to treat viral infections?

No. Levofox is an antibiotic indicated only for treating infections confirmed or strongly suspected to be caused by susceptible bacteria. Regulatory information explicitly states that it is not intended for use against viral infections, such as the common cold or influenza.


Q: What is the typical timeframe for most side effects of Levofox to appear?

The timeframe can vary from patient to patient. Common effects like nausea or headache may start shortly after the first dose. However, official warnings note that certain serious reactions, such as severe allergies or nerve problems, may occur anywhere from within hours to several weeks after beginning the medicine.


Q: Can Levofox affect my ability to drive or operate machinery?

Official labeling advises caution with activities that require focus and alertness, such as driving or operating heavy machinery. This is because side effects affecting the nervous system, including dizziness, confusion, or visual changes, may be observed during treatment.


Q: Does Levofox increase the risk of an aortic aneurysm?

Official warnings from regulatory bodies state that this class of medicine, including Levofox, is associated with an increased risk of aortic aneurysm and dissection (a tear in the wall of the aorta). This risk is particularly noted for older patients and those with pre-existing risk factors.


Q: Is Levofox commonly associated with changes in mood or behavior?

Yes, official documents list a variety of possible central nervous system effects that include changes in mood or behavior. These can include anxiety, agitation, confusion, depression, and hallucinations.


Q: What should I do if I notice a severe reaction after taking Levofox?

Regulatory guidance states that if a severe adverse reaction occurs, such as signs of a serious rash, joint or tendon pain, or changes in sensation, the medicine is required to be discontinued immediately. Official guidance emphasizes that a healthcare provider is required to be contacted without delay in such situations.


Q: Can I use Levofox if I have a known allergy to penicillin?

The medicine is strictly contraindicated only for individuals who have a known hypersensitivity to levofloxacin or any other medicine within the quinolone class. Official information does not establish a direct contraindication based solely on a known allergy to penicillin.


Q: How is Levofox generally eliminated from the body?

According to official pharmacokinetic data, Levofox is primarily removed from the body by the kidneys. It is mostly eliminated as the unchanged active drug in the urine through both filtration and secretion processes.


Q: Is Levofox associated with a risk of Clostridioides difficile infection?

Official warnings note that Levofox, like nearly all antibacterial agents, has been linked to a risk of Clostridioides difficile-associated diarrhea (CDAD). This condition can range in severity from mild diarrhea to a serious, sometimes life-threatening, inflammation of the colon.


Q: What official information is available regarding potential liver problems with Levofox?

Official safety information includes warnings about the potential for hepatotoxicity (liver damage). This damage can be severe and, in rare cases, fatal. Official warnings specify that the medicine is required to be discontinued immediately if any signs of liver injury or hepatitis are observed.


Q: Are there different Levofox doses for different types of infections?

Yes, official prescribing information confirms that the appropriate dosage of Levofox is determined by the specific type and severity of the infection being treated. The dosage is based on specific regulatory guidelines for various approved indications.

How should Levofox be stored and disposed of?

How to Store and Dispose of Levofloxacin

The storage and disposal of Levofloxacin must adhere strictly to the conditions specified in official regulatory labeling to ensure product stability and safety.


Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep from freezing, excessive heat, and moisture. The Solution for Infusion requires protection from light.
Container Keep the medicine in a closed container.
Child Safety Must be kept out of the sight and reach of children.

Disposal

Outdated or unused Levofloxacin must not be discarded into wastewater or routine household trash. Patients are required to consult with a healthcare professional or local pharmacy regarding the correct procedures for disposing of the unused medicine in accordance with local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levofox found in:

A-Z Index: